Literature DB >> 17558976

Is it sound public policy to let the terminally ill access experimental medical innovations?

Arthur Caplan.   

Abstract

Mesh:

Year:  2007        PMID: 17558976     DOI: 10.1080/15265160701429581

Source DB:  PubMed          Journal:  Am J Bioeth        ISSN: 1526-5161            Impact factor:   11.229


× No keyword cloud information.
  5 in total

Review 1.  Product regulation and the clinical translation of stem cell research.

Authors:  Barbara von Tigerstrom
Journal:  Stem Cell Rev Rep       Date:  2009-03-04       Impact factor: 5.739

2.  Innovative Practice, Clinical Research, and the Ethical Advancement of Medicine.

Authors:  Jake Earl
Journal:  Am J Bioeth       Date:  2019-06       Impact factor: 11.229

3.  The 'false hope' argument in discussions on expanded access to investigational drugs: a critical assessment.

Authors:  Marjolijn Hordijk; Stefan F Vermeulen; Eline M Bunnik
Journal:  Med Health Care Philos       Date:  2022-08-11

4.  Expanded Access Programs: Ethical and Practical Considerations for Biopharmaceutical Sponsors.

Authors:  Mitchell Klopfenstein; Luann E Van Campen; Timothy Garnett
Journal:  Ther Innov Regul Sci       Date:  2015-04-02       Impact factor: 1.778

5.  Charlie Gard and the weight of parental rights to seek experimental treatment.

Authors:  Giles Birchley
Journal:  J Med Ethics       Date:  2018-05-17       Impact factor: 5.926

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.